Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Sign Up to like & getrecommendations! Published in 2019 at "Biomedicines"
DOI: 10.3390/biomedicines7030069
Abstract: The alkylating agent temozolomide (TMZ) together with maximal safe bulk resection and focal radiotherapy comprises the standard treatment for glioblastoma (GB), a particularly aggressive and lethal primary brain tumor. GB affects 3.2 in 100,000 people… read more here.
Keywords: agents glioblastoma; temozolomide alkylating; alkylating agents; treatment ... See more keywords